1 Malinowsky K, "uPA and PAI-1-related signaling pathways differ between primary breast cancers and lymph node metastases" 5 : 98-104, 2012
2 Duffy MJ, "uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies" 16 : 428-, 2014
3 Lamy PJ, "Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression" 128 : 404-413, 2007
4 Duffy MJ, "Urokinase-plasminogen activator, a marker for aggressive breast carcinomas:preliminary report" 62 : 531-533, 1988
5 Duffy MJ, "The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer" 37 : 541-548, 2004
6 Tang L, "The urokinase plasminogen activator system in breast cancer invasion and metastasis" 67 : 179-182, 2013
7 Harbeck N, "Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients" 49 : 1825-1835, 2013
8 Remmele W, "Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue" 8 : 138-140, 1987
9 Jänicke F, "Randomized adjuvant chemotherapy trial in high-risk, lymph nodenegative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1" 93 : 913-920, 2001
10 Duffy MJ, "Proteases as prognostic markers in cancer" 2 : 613-618, 1996
1 Malinowsky K, "uPA and PAI-1-related signaling pathways differ between primary breast cancers and lymph node metastases" 5 : 98-104, 2012
2 Duffy MJ, "uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies" 16 : 428-, 2014
3 Lamy PJ, "Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression" 128 : 404-413, 2007
4 Duffy MJ, "Urokinase-plasminogen activator, a marker for aggressive breast carcinomas:preliminary report" 62 : 531-533, 1988
5 Duffy MJ, "The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer" 37 : 541-548, 2004
6 Tang L, "The urokinase plasminogen activator system in breast cancer invasion and metastasis" 67 : 179-182, 2013
7 Harbeck N, "Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients" 49 : 1825-1835, 2013
8 Remmele W, "Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue" 8 : 138-140, 1987
9 Jänicke F, "Randomized adjuvant chemotherapy trial in high-risk, lymph nodenegative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1" 93 : 913-920, 2001
10 Duffy MJ, "Proteases as prognostic markers in cancer" 2 : 613-618, 1996
11 Kantelhardt EJ, "Prospective evaluation of prognostic factors uPA/PAI-1 in nodenegative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel" 11 : 140-, 2011
12 Saadoun H, "Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer" 10 : 195-209, 2014
13 Look MP, "Pooled analysis of prognostic impact of urokinasetype plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients" 94 : 116-128, 2002
14 Castelló R, "Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity" 117 : 487-492, 2006
15 Lei H, "PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer" 109 : 165-175, 2008
16 Lang DS, "Optimized immunohistochemistry in combination with image analysis: a reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer" 22 : 736-743, 2013
17 Isaacs C, "New prognostic factors for breast cancer recurrence" 28 : 53-67, 2001
18 Haas S, "Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue" 452 : 277-283, 2008
19 Hansen S, "Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients" 88 : 102-108, 2003
20 Christensen L, "Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas" 66 : 441-452, 1996
21 Roca C, "Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism" 63 : 1500-1507, 2003
22 Bajou K, "Hostderived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth" 23 : 6986-6990, 2004
23 Andres SA, "Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance" 26 : 93-103, 2012
24 Soff GA, "Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model" 96 : 2593-2600, 1995
25 Dass K, "Evolving role of uPA/uPAR system in human cancers" 34 : 122-136, 2008
26 Leik CE, "Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis" 4 : 2710-2715, 2006
27 Ferrier CM, "Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue" 79 : 1534-1541, 1999
28 Jänicke F, "Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer" 17 : 303-312, 1991
29 Schmitt M, "Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1" 11 : 617-634, 2011